ArticleArthritis and rheumatism2010
Heritability of vasculopathy, autoimmune disease, and fibrosis in systemic sclerosis: a population-based study.
Article in Arthritis and rheumatism, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 50 citations in OpenAlex.
- How do autoimmune diseases cluster in families? A systematic review and meta-analysis.BMC medicine · 2013Pooled it
- Pooled it
- The Phenotypes and Functions of Neutrophils in Systemic Sclerosis.Biomolecules · 2024Review
- Clinical features of pulmonary arterial hypertension associated with systemic sclerosis.Frontiers in medicine · 2023Review
- Animal Models of Systemic Sclerosis: Using Nailfold Capillaroscopy as a Potential Tool to Evaluate Microcirculation and Microangiopathy: A Narrative Review.Life (Basel, Switzerland) · 2022Review
- Trends in Systemic Sclerosis Mortality Over Forty-Eight Years, 1968-2015: A US Population-Based Study.Arthritis care & research · 2021Article
- Raynaud's phenomenon-an update on diagnosis, classification and management.Clinical rheumatology · 2019Review
- Mutations of FAM111B gene are not associated with Systemic Sclerosis.Scientific reports · 2018Article
- Familial risk of systemic sclerosis and co-aggregation of autoimmune diseases in affected families.Arthritis research & therapy · 2016Article
- Eosinophilic Esophagitis in Two Patients with Systemic Sclerosis.Case reports in rheumatology · 2016Article
- Treatment of Rapidly Progressive Systemic Sclerosis: Current and Futures Perspectives.Expert opinion on orphan drugs · 2016Article
- Genetics of systemic sclerosis: recent advances.Current opinion in rheumatology · 2015Review
- Recent advances in the genetics of systemic sclerosis: toward biological and clinical significance.Current rheumatology reports · 2015Review
- The role of genetics and epigenetics in the pathogenesis of systemic sclerosis.Nature reviews. Rheumatology · 2014Review
- Autophagy is a key feature in the pathogenesis of systemic sclerosis.Rheumatology international · 2014Article
- The risk of cardiovascular disease in systemic sclerosis: a population-based cohort study.Annals of the rheumatic diseases · 2013Article
- Systemic sclerosis: current concepts in pathogenesis and therapeutic aspects of dermatological manifestations.Indian journal of dermatology · 2013Article
- Mining electronic health records: an additional perspective.Nature reviews. Genetics · 2013Article
- The pathogenesis, diagnosis and treatment of Raynaud phenomenon.Nature reviews. Rheumatology · 2012Review
- Genetics of systemic sclerosis: an update.Current rheumatology reports · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
objectiveTo investigate the familiality of systemic sclerosis (SSc) in relation to Raynaud's phenomenon (RP) (a marker of vasculopathy), other autoimmune inflammatory disease, and fibrotic interstitial lung disease (ILD).
methodsA genealogic resource, the Utah Population Database (UPDB), was used to test heritability of RP, other autoimmune disease, and ILD. Diseases were defined by International Classification of Diseases, Ninth Revision codes and identified from statewide discharge data, the University of Utah Health Science Center Enterprise Data Warehouse, and death certificates and were linked to the UPDB for analysis. Familial standardized incidence ratio (FSIR), relative risks (RRs) to first-, second-, third-, and fourth-degree relatives for SSc, RP, other autoimmune disease, and ILD (with 95% confidence intervals [95% CIs]), and population attributable risk (PAR) were calculated.
resultsA software kinship analysis tool was used to analyze 1,037 unique SSc patients. Fifty SSc families had significant FSIRs, ranging from 2.07 to 17.60. The adjusted PAR was approximately 8%. The RRs were significant for other autoimmune disease in the first-degree relatives (2.49 [95% CI 1.99-3.41], P = 2.42 x 10(-15)) and second-degree relatives (1.48 [95% CI 1.34-2.39], P = 0.002), for RP in first-degree relatives (6.38 [95% CI 3.44-11.83], P = 4.04 x 10(-9)) and second-degree relatives (2.39 [95% CI 1.21-4.74], P = 0.012), and for ILD in first-degree relatives (1.53 [95% CI 1.04-2.26], P = 0.03), third-degree relatives (1.47 [95% CI 1.18-1.82], P = 0.0004), and fourth-degree relatives (1.2 [95% CI 1.06-1.35], P = 0.004).
conclusionThese data suggest that SSc pedigrees include more RP, autoimmune inflammatory disease, and ILD than would be expected by chance. In SSc pedigrees, genetic predisposition to vasculopathy is the most frequent risk among first-degree relatives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.